Adicet Bio stock rating initiated at Buy by H.C. Wainwright

Published 23/07/2025, 13:34
Adicet Bio stock rating initiated at Buy by H.C. Wainwright

Investing.com - H.C. Wainwright has initiated coverage on Adicet Bio Inc. (NASDAQ:ACET) with a Buy rating and a $4.00 price target, according to a research note released Wednesday. The stock, currently trading at $0.75 with a market cap of $62.2 million, shows potential upside according to InvestingPro analysis, which indicates the stock is currently undervalued.

The coverage initiation focuses on Adicet’s ADI-270, an armored CD70-targeted allogeneic gamma delta CAR-T cell therapy candidate incorporating a third-generation CAR design. This therapy is currently being evaluated in a Phase 1 trial for CD70+ cancers and has received FDA Fast Track Designation for treating metastatic/advanced clear cell renal cell carcinoma (ccRCC) in patients previously treated with immune checkpoint and VEGF inhibitors. InvestingPro data shows the company maintains a strong current ratio of 9.34, with more cash than debt on its balance sheet, providing runway for its clinical development programs.

H.C. Wainwright highlighted preclinical data showing ADI-270’s ability to maintain proliferation and cytotoxicity in immunosuppressive environments, as well as demonstrating greater cytotoxicity in CD70-low tumors compared to CAR αβ T cell references.

The research firm referenced Allogene Therapeutics’ (NASDAQ:ALLO) ALLO-316 data presented at ASCO 2025, which showed a 25% overall response rate in heavily pretreated ccRCC patients, with a 31% response rate in patients with CD70 TPS > 50%.

Preliminary data for ADI-270 in ccRCC is expected in the second half of 2025, with initial Phase 1 trial results slated for release by the end of 2025, which H.C. Wainwright described as a "partially risk-mitigated data catalyst" supporting their Buy rating. With analyst targets ranging from $4 to $8, investors seeking deeper insights can access comprehensive analysis and 12 additional ProTips through InvestingPro’s detailed research report.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.